2022年10月25日

Los Altos Alto神经科学,总部neuro-tech公司专门从事精密精神病学,提出了m系列B 35美元融资。圆是由Lightswitch资本和Alkeon首都Sobrato资本的参与,诺华制药公司英勇Equity Partners, Korify资本,葡萄树,Gaingels, Apeiron组,尼企业,温德姆合资企业的合作伙伴。结合B系列融资,Lightswitch资本的首席执行官,克里斯托弗·考克斯和Alkeon资本董事总经理Jeff Chen博士加入中音的董事会。此外,鲍勃Baloh,医学博士,Ph.D., global head of neuroscience at the Novartis Institutes for BioMedical Research (NIBR), will join as a board observer. The company intends to use the funds to advance lead candidates into Phase 2b studies in major depressive disorder in addition to continued development on other programs within its clinical-stage precision psychiatry pipeline. Proceeds from the financing will also be used to progress the company’s artificial intelligence-enabled brain biomarker platform and launch new clinical trials in areas of high unmet medical need. Alto will report Phase 2a data in early 2023 and further anticipates Phase 2b data readouts by early 2024. Led by Amit Etkin, M.D., Ph.D., founder and chief executive officer, Alto Neuroscience provides a precision psychiatry by developing targeted medicines to help patients get better. Differences in individuals’ biology impact how they respond to treatment. Its Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, behavioral task performance, wearable data, genetics, and other factors to match each patient with the right Alto drug. The company’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, and other mental health conditions, resulting in the broadest and most-advanced precision psychiatry effort. FinSMEs 26/10/2022